Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
2HSecond half of the year
5-ASA, 5-ASAs, 5ASA5-Aminosalicylic acid
ABX464, ABX-464Abivax development code for obefazimod
ABX464-N-Glu, ABX464-NGlcABX464 N-glucuronide, a pharmacologically active metabolite of obefazimod
ACGAmerican College of Gastroenterology
ACTActive Ulcerative Colitis Trial (ACT 1 and ACT 2, infliximab)
AdjMAdjusted mean
AE, AEsAdverse event
AESI, AESIsAdverse event of special interest
AGAAmerican Gastroenterological Association
AHFSAmerican Hospital Formulary Service
AhRAryl hydrocarbon receptor
aHRAdjusted hazard ratio
ALTAlanine aminotransferase
ANCOVAAnalysis of covariance
ANOVAAnalysis of variance
ASCAAnti-Saccharomyces cerevisiae antibodies
ASPAverage sales price
ASTAspartate aminotransferase
ASUCAcute severe ulcerative colitis
AT, ATsAdvanced therapy
AT-IR, ATIRInadequate response to advanced therapy
ATCAnatomical Therapeutic Chemical (classification code)
AUCArea under the concentration-time curve
AUC0-inf, AUC0–∞Area under the concentration-time curve from time 0 to infinity
AUC0-t, AUC0–tArea under the concentration-time curve from time 0 to the last measurable concentration
BDDBaseline disease duration
BGDBetween-group difference
BIDTwice daily
BMI, BMIsBody mass index
BOLSBaseline of Open Label Study
BSGBritish Society of Gastroenterology
BTLBottle (package description)
BUBowel urgency
CAPCapsule (package description)
CASChemical Abstracts Service
CBCComplete blood count
CCL2C-C motif chemokine ligand 2
CDCrohn's disease
CD4Cluster of differentiation 4
CESTCentral European Summer Time
CIConfidence interval
CmaxMaximum plasma concentration
CMHCochran-Mantel-Haenszel
CMOsContract manufacturing organizations
CMSCenters for Medicare & Medicaid Services
CMVCytomegalovirus
COVID-19Coronavirus disease 2019
CPKCreatine phosphokinase
CR-ICoalescing range for incidence
CR-PCoalescing range for prevalence
CRC, CRCsColorectal cancer
CRPC-reactive protein
CRSClinical Research Services (CRS Clinical Research Services Management GmbH)
CRsCoalescing ranges
CSCorticosteroid
CTCount (package description)
CTC-AE, CTCAECommon Terminology Criteria for Adverse Events
CV, CVsCardiovascular; coefficient of variation
CXCL12C-X-C motif chemokine ligand 12
CYCalendar year
CYP, P450Cytochrome P450
CYP1A2Cytochrome P450 1A2
D28, D56Day 28, day 56
DDIDrug-drug interaction
ddPCRDroplet digital polymerase chain reaction
DILIDrug-induced liver injury
DILIsymDrug-induced liver injury simulation software
DLTDose-limiting toxicity
DSMBData Safety Monitoring Board
DSSDextran sulfate sodium
DVTDeep vein thrombosis
E1, E2, E3Montreal classification of disease extent: proctitis (E1), left-sided colitis (E2), extensive colitis (E3)
ECCOEuropean Crohn's and Colitis Organisation
ECGElectrocardiogram
EDEmergency department
EEAEuropean Economic Area
EIMsExtraintestinal manifestations
EL3, EL4Evidence level 3, evidence level 4
EMAEuropean Medicines Agency
EOSEnd of Study
EQ-5DEuroQol 5-Dimension
EQ-5D-5LEuroQol 5-Dimension, 5-Level
EREmergency room
ESRErythrocyte sedimentation rate
EUEuropean Union
EU5France, Germany, Italy, Spain, and the United Kingdom
EudraCTEuropean Union Drug Regulating Authorities Clinical Trials Database
evLYEqual value life-year
FACIT-FatigueFunctional Assessment of Chronic Illness Therapy-Fatigue
FASFull Analysis Set
FC, FCPFecal calprotectin
FDAU.S. Food and Drug Administration
GM, GMsGeometric mean
GM-CSFGranulocyte-macrophage colony-stimulating factor
GmbHGesellschaft mit beschränkter Haftung (limited liability company)
HBVHepatitis B virus
HCP, HCPsHealth care provider
HCRUHealth care resource utilization
HCUPHealthcare Cost and Utilization Project
HEMI, HEMI1Histologic-endoscopic mucosal improvement
HIVHuman immunodeficiency virus
HLAHuman leukocyte antigen
HLA-B27Human leukocyte antigen B27
HPAHypothalamus-pituitary-adrenal
HRHazard ratio; hour (in a product description)
HRAHealth Research Authority (United Kingdom)
HRQoLHealth-related quality of life
HSTCLHepatosplenic T-cell lymphoma
I2I-squared statistic of heterogeneity
IBD, IBDsInflammatory bowel disease
IBD-FCIBD-fibrotic cytokine cocktail
IBDQInflammatory Bowel Disease Questionnaire
IBSENInflammatory Bowel South-Eastern Norway (cohort study)
ICIndeterminate colitis
ICD-10International Classification of Diseases, Tenth Revision
ICERInstitute for Clinical and Economic Review
ICVSCIndependent Cardiovascular Safety Committee
IDIdentifier
IE, IEsIntercurrent event
IEC-IRBIndependent Ethics Committee-Institutional Review Board
IFNγInterferon gamma
IgG1Immunoglobulin G1
IgG1λImmunoglobulin G1 lambda
IgG4Immunoglobulin G4
ILInterleukin
IL-12/23Interleukin 12 and interleukin 23
IL-13Interleukin 13
IL-17Interleukin 17
IL-17A, IL17aInterleukin 17A
IL-22Interleukin 22
IL-23, IL23Interleukin 23
IL-4, IL4Interleukin 4
IL-5Interleukin 5
IL-6, IL6Interleukin 6
IL10Interleukin 10
IL1bInterleukin 1 beta
IL23p19p19 subunit of interleukin 23
IL34Interleukin 34
IL6rInterleukin 6 receptor
IMPInvestigational medicinal product
INNInternational Nonproprietary Name
IPAAIleal pouch-anal anastomosis
IQRInterquartile range
IR, IRsInadequate response; incidence rate (IR/100 PY)
IRAIleorectal anastomosis
ISBInduction Study Baseline
ITTIntention-to-treat
IUSIntestinal ultrasound
IVIntravenous
IVCSIntravenous corticosteroids
JAK, JAKsJanus kinase
JAK-1Janus kinase 1
JAK-IRInadequate response to a Janus kinase inhibitor
JAKiJanus kinase inhibitor
LANCL2Lanthionine synthetase C-like protein 2
LFTsLiver function tests
LIFLeukemia inhibitory factor
LOCFLast observation carried forward
LPSLipopolysaccharide
LSM, LSMeansLeast squares mean
LTELong-term extension
M1, M2, M3, M12, M24, M48Month 1, month 2, month 3, month 12, month 24, month 48
MACEMajor adverse cardiovascular events
MCP1Monocyte chemoattractant protein 1
MCSMayo Clinic Score
MESMayo endoscopic subscore
MIPSMerit-based Incentive Payment System
miR-124, MiR-124, miR124, miRNA-124MicroRNA-124
miRNAMicroRNA
MMS, mMSModified Mayo Score
MMXMulti-Matrix System
MOAsMechanisms of action
mRNAMessenger ribonucleic acid
MWPCMeaningful within patient change
N/ANot applicable
NBMNocturnal bowel movements
NCNot calculated
NCINational Cancer Institute
NDANew Drug Application
NHBNet health benefit
NIMPNon-investigational medicinal product
NISNational Inpatient Sample
NMANetwork meta-analysis
NMSC, NMSCsNonmelanoma skin cancer
NNTNumber needed to treat
NRINonresponder imputation
NRSNumerical Rating Scale
NSAIDNonsteroidal anti-inflammatory drug
NT-proBNPN-terminal pro-B-type natriuretic peptide
NYHANew York Heart Association
OATP1B1, 1B3Organic anion-transporting polypeptide 1B1 and 1B3
Obe-25, Obe-50Obefazimod 25 mg, obefazimod 50 mg
OCObserved Cases
OLEOpen-label extension
OLMOpen-label maintenance
OR, ORsOdds ratio
pANCAPerinuclear antineutrophil cytoplasmic antibodies
PBMCsPeripheral blood mononuclear cells
PBOPlacebo
PBTLPlastic bottle (package description)
PDE-4Phosphodiesterase 4
PDsProtocol deviations
Ph.D.Doctor of Philosophy
PIPrincipal investigator
PIPPaediatric investigation plan
PKPharmacokinetics
PMLProgressive multifocal leukoencephalopathy
pMMSPartial Modified Mayo Score
pMSPartial Mayo score
PPPer protocol
PPASPer Protocol Analysis Set
pre-mRNAPrecursor messenger ribonucleic acid
PRESPosterior Reversible Encephalopathy Syndrome
PRO, PROsPatient-reported outcome
PRO-C3N-terminal propeptide of type III collagen
PRO2Two-item patient-reported outcome (stool frequency and rectal bleeding)
PSCPrimary sclerosing cholangitis
PYPatient-years
Q3, Q4Third quarter, fourth quarter
QALY, QALYsQuality-adjusted life-year
QDOnce daily
QoLQuality of life
qPCRQuantitative polymerase chain reaction
QTQT interval of the electrocardiogram
QTcQT interval corrected for heart rate
RARheumatoid arthritis
RBSRectal bleeding subscore
RCT, RCTsRandomized controlled trial
RNARibonucleic acid
RNAiRNA interference
RRRisk ratio
S1P, S1PsSphingosine-1-phosphate
SAE, SAEsSerious adverse event
SAFSafety Analysis Set
SARS Cov-2Severe acute respiratory syndrome coronavirus 2
SCSubcutaneous
SCCAISimple Clinical Colitis Activity Index
SCFAShort-chain fatty acid
SDStandard deviation
SF-3636-Item Short Form Health Survey
SFSStool frequency subscore
SGOTSerum glutamic-oxaloacetic transaminase
SGPTSerum glutamic-pyruvic transaminase
SIBDQShort Inflammatory Bowel Disease Questionnaire
SIRStandardized incidence ratio
SMRStandardized mortality ratio
STAT3Signal transducer and activator of transcription 3
STRIDE-I, STRIDE-IISelecting Therapeutic Targets in Inflammatory Bowel Disease, first and second consensus
t1/2Elimination half-life
TBTuberculosis
TEAE, TEAEsTreatment-emergent adverse event
TESAEsTreatment-emergent serious adverse events
TFCFilm-coated tablet (package description)
Th1, Th17T helper type 1 cell, T helper type 17 cell
TIMsTargeted immune modulators
TL1ATumor necrosis factor-like ligand 1A
TmaxTime to maximum plasma concentration
TMS, tMSTotal Mayo Score
TNBS2,4,6-Trinitrobenzene sulfonic acid
TNFTumor necrosis factor
TNF-α, TNFα, TNF-alphaTumor necrosis factor alpha
TPOThrombopoietin
UCUlcerative colitis
UEGUnited European Gastroenterology
UGTIA9Uridine diphosphate glucuronosyltransferase 1A9 (printed as UGTIA9 in the source)
UKUnited Kingdom
ULNUpper limit of normal
US, U.S.United States
USA, U.S.A.United States of America
USDUnited States dollar
V5.0Version 5.0
VASVisual analog scale
VTEVenous thromboembolism
W8, W48, W96, W144Week 8, week 48, week 96, week 144
WAC, WACsWholesale acquisition cost
WHOWorld Health Organization
WOCBPWomen of childbearing potential
WPAIWork Productivity and Activity Impairment
WPAI-UCWork Productivity and Activity Impairment questionnaire for ulcerative colitis
XRExtended release
α-SMAAlpha-smooth muscle actin